Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States

BACKGROUND: Metastatic prostate cancer is initially sensitive to androgen receptor inhibition, but eventually becomes metastatic castration-resistant prostate cancer (mCRPC). Olaparib has longer progression-free survival and better measures of response and patient-reported end points than either enz...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chenxia, Cai, Jiaqin, Zhuang, Jie, Zheng, Bin, Chen, Li, Sun, Hong, Zheng, Guiyan, Wei, Xiaoxia, Liu, Maobai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403933/
https://www.ncbi.nlm.nih.gov/pubmed/36034977
http://dx.doi.org/10.21037/atm-22-3637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403933/
https://www.ncbi.nlm.nih.gov/pubmed/36034977
http://dx.doi.org/10.21037/atm-22-3637

Ejemplares similares